HIGH RISK SMOLDERING MULTIPLE MYELOMA
Clinical trials for HIGH RISK SMOLDERING MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new HIGH RISK SMOLDERING MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for HIGH RISK SMOLDERING MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a powerful drug cocktail halt multiple myeloma before it starts?
Disease control OngoingThis phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…
Matched conditions: HIGH RISK SMOLDERING MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 05:00 UTC
-
Four-Drug cocktail aims to halt smoldering myeloma before it strikes
Disease control OngoingThis phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria.…
Matched conditions: HIGH RISK SMOLDERING MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Omar Nadeem, MD • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Promising combo aims to stop smoldering myeloma in its tracks
Disease control OngoingThis phase 3 trial tests whether adding isatuximab (Sarclisa) to standard lenalidomide and dexamethasone can delay progression to active multiple myeloma in people with high-risk smoldering myeloma. About 337 participants will receive either the three-drug combo or the two-drug s…
Matched conditions: HIGH RISK SMOLDERING MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC